WILLIS TOWERS WATSON PLC — Director's Dealing 2020

Jul 14, 2020

National Storage Mechanism | Additional information

RNS Number : 0058T

Willis Towers Watson PLC

14 July 2020

Ap9

APPENDIX 3 DISCLOSURE FORMS

FORM 8.1(a)&(b)(i)

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS

1.       KEY INFORMATION

Name of person dealing (Note 1)	John Haley
Company dealt in	Willis Towers Watson plc
Class of relevant security to which the dealings being disclosed relate (Note 2)	Ordinary Shares of $0.000304635 each
Date of dealing	9 July 2020

2.         INTERESTS AND SHORT POSITIONS

(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long			Short
	Number		(%)	Number		(%)
(1) Relevant securities	Ordinary Shares: 124,927 (0.097%)
(2) Derivatives (other than options)	N/A
(3) Options and agreements to purchase/sell	RSU's pursuant Willis Towers Watson Non-Qualified Deferred Savings Plan for U.S. Employees: 108,673 (0.084%)
Total	233,600 (0.181%)

(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:	Long			Short
	Number		(%)	Number		(%)
(1) Relevant securities	N/A
(2) Derivatives (other than options)	N/A
(3) Options and agreements to purchase/sell	Options: 150,235 (0.116%) Vested WTW Shares that will settle upon termination of service: 274,134 (0.212%) RSU's under the non-qualified stable value excess plan: 9,770 (0.007%) Dividend equivalent rights accrued on ordinary shares earned under performance based RSS award: 4,814 (0.003%) 2020 long-term incentive performance based RSU award (unearned): 47,374 (0.036%) 2019 long term- incentive performance based RSU award (unearned): 53,996 (0.041%)
Total	540,324 (0.419%)

Ap10

3.       DEALINGS (Note 4)

(a)      Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit (Note 5)

(b)      Derivatives transactions (other than options transactions)

Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit (Note 5)

(c)      Options transactions in respect of existing relevant securities

(i)       Writing, selling, purchasing or varying

Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)
RSU pursuant Willis Towers Watson Non-Qualified Deferred Savings Plan for U.S. Employees	Accrual of RSU's	91	N/A	N/A	N/A	$199.02
RSU pursuant Willis Towers Watson Non-Qualified Deferred Savings Plan for U.S. Employees	Accrual of RSU's	53	N/A	N/A	N/A	$0

(ii)      Exercising

Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)

(d)      Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)	Details	Price per unit (if applicable) (Note 5)

Ap11

4.       OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

N/A

Is a Supplemental Form 8 attached? (Note 9)                                            NO

Date of disclosure	14 July 2020
Contact name	Nicole Napolitano
Telephone number	+1 (212) 915-8098
Name of offeree/offeror with which acting in concert	Willis Towers Watson plc
Specify category and nature of acting in concert status	Director

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

ISEGPUAGMUPUGMC